The Influence of Adiponectin Gene Polymorphism on the Rosiglitazone Response in Patients With Type 2 Diabetes
- Eun Seok Kang, MD, PHD1,
- So Young Park, MD1,
- Hyeong Jin Kim, MD2,
- Chul Woo Ahn, MD, PHD1,
- Moonsuk Nam, MD, PHD3,
- Bong Soo Cha, MD, PHD1,
- Sung Kil Lim, MD, PHD1,
- Kyung Rae Kim, MD, PHD1 and
- Hyun Chul Lee, MD, PHD1
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
- 2Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea
- 3Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea
- Address correspondence and reprint requests to Hyun Chul Lee, Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong Seodaemun-Gu, Seoul, 120-752, Korea. E-mail: endohclee{at}yumc.yonsei.ac.kr
Abstract
OBJECTIVE —The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms.
RESEARCH DESIGN AND METHODS —A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined.
RESULTS —Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA1c value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA1c levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygote haplotype was smaller than that of the other haplotypes (P = 0.003).
CONCLUSIONS —These data suggest that genetic variations in the adiponectin gene can affect the rosiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.
- FPG, fasting plasma glucose
- HOMA-IR, homeostasis model assessment of insulin resistance
- PPAR, peroxisome proliferator–activated receptor
- PPRE, PPAR responsive element
- SNP, single nucleotide polymorphism.
Footnotes
-
Additional information for this article can be found in an online appendix at http://care.diabetesjournals.org.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted January 23, 2005.
- Received August 16, 2004.
- DIABETES CARE
